197 related articles for article (PubMed ID: 23422917)
1. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.
Werth BJ; Vidaillac C; Murray KP; Newton KL; Sakoulas G; Nonejuie P; Pogliano J; Rybak MJ
Antimicrob Agents Chemother; 2013 May; 57(5):2376-9. PubMed ID: 23422917
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
[TBL] [Abstract][Full Text] [Related]
3. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
Tran N; Rybak MJ
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
[TBL] [Abstract][Full Text] [Related]
5. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
Werth BJ; Sakoulas G; Rose WE; Pogliano J; Tewhey R; Rybak MJ
Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
[TBL] [Abstract][Full Text] [Related]
8. In vitro synergistic effects of various combinations of vancomycin and non-beta-lactams against Staphylococcus aureus with reduced susceptibility to vancomycin.
Kang YR; Chung DR; Kim J; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Song JH
Diagn Microbiol Infect Dis; 2016 Nov; 86(3):293-299. PubMed ID: 27591174
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
Ozmen Capin BB; Tekeli A; Karahan ZC
Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
[No Abstract] [Full Text] [Related]
12. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
Saravolatz L; Pawlak J; Johnson L
Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122
[TBL] [Abstract][Full Text] [Related]
14. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.
Hu J; Ma XX; Tian Y; Pang L; Cui LZ; Shang H
PLoS One; 2013; 8(9):e73300. PubMed ID: 24069184
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
Werth BJ; Steed ME; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
[TBL] [Abstract][Full Text] [Related]
18. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Vidaillac C; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]